GlobalData on MSN3mon
MSD’s CAPVAXIVE vaccine shows promise in pneumococcal disease trial
MSD’s CAPVAXIVE vaccine has demonstrated promising results from the STRIDE-8 Phase III trial, which showed positive immune ...
Hosted on MSN7mon
Merck Capvaxive pneumonia vaccine recommended by CDC advisors
Merck (NYSE:MRK) announced that a group of independent advisors to the U.S. CDC unanimously voted to recommend its newly approved pneumonia vaccine, Capvaxive, for adults aged 65 years and older.
pharmaphorum2d
FDA says yes to MSD’s 21-valent adult pneumococcal jab
The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...
Barron's7mon
Merck Prepares to Take on Pfizer After Pneumococcal Vaccine Approval
FDA approval of Merck’s new pneumococcal vaccine, Capvaxive, tees up a new challenge to one of Pfizer’s most important products.
Merck & Company: Strategic Shifts and Upcoming Catalysts Amidst Keytruda Challenges
Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target ...